QuidelOrtho Corporation (NASDAQ:QDEL – Get Free Report) has been given an average recommendation of “Reduce” by the six ratings firms that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $13.6250.
A number of research analysts recently commented on the stock. Wall Street Zen raised shares of QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. UBS Group reiterated a “neutral” rating and issued a $12.00 price target on shares of QuidelOrtho in a research report on Thursday, May 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research report on Friday, July 17th. Citigroup increased their target price on QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, JPMorgan Chase & Co. boosted their price target on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a report on Wednesday, July 1st.
Check Out Our Latest Stock Analysis on QDEL
QuidelOrtho Trading Up 3.9%
QuidelOrtho (NASDAQ:QDEL – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.18. The firm had revenue of $630.90 million for the quarter, compared to analysts’ expectations of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The firm’s revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.12 earnings per share. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Equities research analysts predict that QuidelOrtho will post 0.75 EPS for the current fiscal year.
Institutional Investors Weigh In On QuidelOrtho
Several institutional investors and hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. raised its holdings in shares of QuidelOrtho by 7.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after buying an additional 819,908 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of QuidelOrtho during the second quarter worth $196,212,000. Newtyn Management LLC lifted its position in shares of QuidelOrtho by 45.3% during the 2nd quarter. Newtyn Management LLC now owns 6,625,000 shares of the company’s stock valued at $116,037,000 after acquiring an additional 2,066,528 shares during the period. Invesco Ltd. lifted its stake in shares of QuidelOrtho by 19.4% in the 4th quarter. Invesco Ltd. now owns 3,470,656 shares of the company’s stock valued at $99,122,000 after acquiring an additional 563,893 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of QuidelOrtho by 7.5% in the first quarter. Dimensional Fund Advisors LP now owns 3,048,768 shares of the company’s stock worth $50,085,000 after purchasing an additional 212,481 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.
About QuidelOrtho
QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.
The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.
Featured Articles
- Five stocks we like better than QuidelOrtho
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.
